clinical trial · NCT07213791
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company·phase1·recruiting·n = 241
Ovarian NeoplasmsBreast NeoplasmsPancreatic Intraductal NeoplasmsColorectal NeoplasmsEsophageal NeoplasmsStomach NeoplasmsCholangiocarcinomaLY4337713
brief summary
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
started
Oct 22, 2025
primary completion
Jul 1, 2028
completion
Mar 1, 2033
last updated
Jun 4, 2026
official title
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol